

Beyond Medical Technologies Inc.

1 ? . Z ((f \$ L & \$ + - , - \$, %
 B 5 . Z % * (* , - * ' \$ *)
 5 1 Z * % & ' - & , \$ \$ + \$ \$
 U W j c b 4 d f c U W i j Y j b j Y g r c f g " V e a

06:30 10 Sep 2020

Micron Waste Technologies making strides in the huge organic waste industry and has also acquired a PPE manufacturer

- Has developed a proprietary process that breaks down organic waste
- Food waste management is a multi-billion dollar industry
- Has completed acquisition of manufacturer Covid Technologies

What Micron Waste Technologies does:

Micron Waste Technologies Inc (CSE:MWM) (OTCMKTS:MICWF) describes itself as a leading organic waste technology company based in Canada.

The group's on-site treatment system turns organic waste into clean water. Its technology can handle specialized organic waste generated by cannabis cultivators, food producers and operators, hotels and others.

Food waste management is a multi-billion dollar industry, the Vancouver-based firm says, with Canada alone throwing away food worth \$31 billion every year. Micron says its technology is unique and clean and can manage food, but also cannabis and other organic matter.

The benefits of its process include that it reduces greenhouse gas emissions, saves landfill space, minimizes waste disposal costs and preserves fresh water resources.

Significantly, on July 10 this year, in a move which added another string to its bow, Micron said it had completed its acquisition of personal protective equipment (PPE) manufacturer Covid Technologies Inc.

It issued to former Covid Technologies securityholders around 16.5 million common shares at C\$0.08 per consideration share as well as 16.5 million replacement warrants exercisable into shares at \$0.10 each for a period up to and including April 28, 2025.

How is it doing:

When it completed the Covid Technologies Inc deal on July 10, Micron said the business was preparing to deliver Canadian-made, high quality, vapour barrier technology (masks and garments) that protect against biological hazards, pathogens and subbugs, a key product in the coronavirus (COVID-19) pandemic world.

The materials will be made at Micron Waste's facility in Delta, British Columbia. Covid Technologies also plans to make N95 Respirators and is awaiting a licence from the National Institute for Occupational Safety and Health to be able to begin production.


Micron Waste confirmed it will continue the research and development of its waste digester business alongside the PPE manufacturing business.

In particular, the Pharmavore digester is anticipated to enter testing and trials with an industry partner, the company

Price: 0.14

Market Cap: \$7.84 m

1 Year Share Price Graph



Share Information

Code: DOCT

Listing: CSE

52 week High Low
 0.195 0.13

Sector: Tech

Website: micronti.com

Company Synopsis:

Micron is a well-funded industrial/technology company with a manufacturing facility based in Delta, BC. It is developing waste digesters using proprietary technology. Its waste digester business is focused on the cannabis and food industry with its Cannivore, Organivore and Pharmavore waste digesters.

action@proactiveinvestors.com

said, adding that it had over \$3 million to allocate to its waste digester business and it is anticipated that the PPE business line will be self-financing based on anticipated sales.

Inflection points:

- More newsflow/deals
- PPE sales and production ramp-up

What the boss says:

In May, Covid Technologies president and now Micron Waste board director, Harvey Sidhu spoke to Proactive's Steve Darling and explained how the company had entered the personal protective equipment (PPE) space after he realized the strength of demand for such products in Canada.

Striking a deal with Micron Waste helps to scale up production, explained Sidhu.

"We want to be able to make Canadian made products for Canadians," he said. "When there is a huge demand, we can't rely on other countries for PPE equipment for our frontline workers," he added.

The firm can currently make about 100,000 surgical face masks a day and for the N95 facepiece respirator about 40,000 but the demand is very high and Sidhu said he wanted to ramp that up.

Contact the author at giles@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Beyond Medical Technologies Inc. named herein, including the promotion by the Company of Beyond Medical Technologies Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).